Document is current
Any future updates will be listed below
-
Authors
Yang, Sen
Liu, Yang
Zhao, Jiuzhou
He, Zhen
Chen, Haiyang
Ma, Shuxiang
Wu, Yingxi
Wu, Yufeng
Wang, Lili
Zhang, Cuicui
Wang, Qiming
-
Funding
Funding for this research was provided by:
Wu Jie-ping Clinical Research Fund (320.6750.2021-02-121)
The Excellent Young Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (YXKC2022050)
Key Research and Development Projects of Henan Province in 2023 - Key technologies of novel precision immunotherapy for refractory malignant tumors (231111313300)
Henan Province Health and Youth Subject Leader Training Project ([2020]60)
Key project of medical science and technology in Henan Province (SBGJ202101009)
Leading Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (YXKC2020009)
ZHONGYUAN QIANREN JIHUA (ZYQR201912118)
Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer ([2021]10)
Henan Refractory Lung Cancer Drug Treatment Engineering Technology Research Center ([2020]4)
Henan Medical Key Laboratory of Refractory lung cancer ([2020]27)
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 12 May 2025
First Online: 20 May 2025
Declarations
:
: This study has been approved by the Ethics Committee of the Affiliated Cancer Hospital of Zhengzhou University (2022-247-003), adhering to Helsinki Declaration, with informed consent waived due to its retrospective nature.
: This manuscript has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal. All the authors have approved the manuscript and agree with submission to your esteemed journal.
: The authors declare no competing interests.
